Before we conduct the combination therapy, we explored the dosage of anti-PD-1 monoclonal antibody in HCC mice model with 50μg, 100μg and 150μg doses respectively treated with TLR9 agonist. Here, TLR9 is linked to hepatocellular carcinoma.